RL
NKGN

RPO LLC’s NKGen Biotech, Inc. Common Stock NKGN Stock Holding History

RPO LLC’s Portfolio NKGN Stock Details NKGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-237,001
Closed -$2.4M – 106
2023
Q1 		$2.4M Buy
237,001
+47,001
+25% +$474K 0.73% 41
2022
Q4 		$1.89M Buy
+190,000
New +$1.88M 0.65% 51

Other funds holding NKGN

RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
FTCM
Fir Tree Capital Management New York $21.8M AUM 1.61% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
SIM
Sandia Investment Management Boston, Massachusetts $40.1M AUM 14.58% 1-Year Est. Return
SFM
Spartan Fund Management Toronto, Ontario, Canada $30M AUM 11.98% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
KL
KIM LLC Wichita, Kansas $976M AUM 0.91% 1-Year Est. Return

RPO LLC's NKGN Position: Q2 2023 in Review

RPO LLC sold out of NKGen Biotech, Inc. Common Stock (NKGN) in Q2 2023, closing a stake of 237,001 shares — an estimated $2.4M sold.

RPO LLC first reported a position in NKGN in Q4 2022 and held it in 2 quarters. The position peaked at $2.4M in Q1 2023. 25 funds tracked by Wall St. Rank hold NKGN as of Q2 2023.

  • RPO LLC reported no remaining NKGen Biotech, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • RPO LLC sold 237,001 NKGen Biotech, Inc. Common Stock shares in Q2 2023, an estimated $2.4M.
  • RPO LLC first reported a position in NKGen Biotech, Inc. Common Stock in Q4 2022 and held it in 2 quarters.
  • RPO LLC's NKGen Biotech, Inc. Common Stock position peaked at $2.4M in Q1 2023.
  • 25 funds tracked by Wall St. Rank held NKGen Biotech, Inc. Common Stock as of Q2 2023.

Based on RPO LLC's 13F filing for Q2 2023, filed 9 Aug 2023.